alisertib alisertib alisertib (mln8237) is an orally available selective aurora a kinase inhibitor developed by takeda. it was investigated as a treatment for relapsed or refractory peripheral t-cell lymphoma. development was abandoned in 2015 due to poor clinical trial results. alisertib names preferred iupac name 4--2-methoxybenzoic acid identifiers cas number 1028486-01-2 3d model (jsmol) interactive image chembl chembl483158 chemspider 24700147 iuphar/bps 7790 kegg d10085 pubchem cid 24771867 unii t66es73m18 comptox dashboard (epa) dtxsid30145539 inchi inchi=1s/c27h20clfn4o4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13h,12h2,1-2h3,(h,34,35)(h,31,32,33)key: zlhfilgsqdjulk-uhfffaoysa-ninchi=1/c27h20clfn4o4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13h,12h2,1-2h3,(h,34,35)(h,31,32,33)key: zlhfilgsqdjulk-uhfffaoyab smiles coc1=c(c(=cc=c1)f)c2=ncc3=cn=c(n=c3c4=c2c=c(c=c4)cl)nc5=cc(=c(c=c5)c(=o)o)oc properties chemical formula c27h20clfn4o4 molar mass 518.93 g·mol−1 except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). infobox references